Phase 2 sacituzumab tirumotecan TROP2-directed ADC (topoisomerase I payload) in post-platinum NEPC.

This Phase 2, open-label, single-arm study tests sacituzumab tirumotecan (a TROP2-targeting monoclonal antibody–drug conjugate carrying a belotecan-derived topoisomerase I inhibitor payload) in metastatic neuroendocrine prostate cancer that has progressed after platinum-based chemotherapy. The purpose is to define anti-tumor activity and safety in an aggressive subtype where responses to available regimens are often short-lived. Eligible patients have metastatic NEPC with progression on prior platinum, aligning the trial with a high-unmet-need, chemo-refractory population. Virginia Commonwealth University sponsors the study at its Richmond site, while the scientific angle is extending the clinical “TROP2-ADC” playbook (validated commercially in other tumors) into NEPC, where targetable drivers are limited and drug delivery to rapidly proliferative disease may matter. Today’s care after platinum typically moves to additional cytotoxic regimens (often borrowing from small-cell paradigms) and supportive care, with few established targeted options for NEPC.